Pfizer, BioNTech amend Covid-19 vaccine supply deal with EC

Pfizer and BioNTech have amended the supply agreement with the European Commission (EC) to rephase the delivery schedules of their Covid-19 vaccine. The Pfizer-BioNTech COVID-19 Vaccine is based on the messenger ribonucleic acid (mRNA) technology of BioNTech. Under the deal, the initial contractual supply schedules for the vaccine will be updated to rephase the supplies to support the vaccination programmes of EC and its member states.